Skip to content
    LifeArc Ventures logo

    LifeArc Ventures

    London, United KingdomFounded 2019

    LifeArc Ventures is the venture investment arm of LifeArc, a self-funded medical research charity. It invests in early-stage, science-led therapeutics and healthtech companies from seed to Series B, providing scientific insight, advice, and venture funding, with financial returns reinvested into LifeArc's charitable mission.

    39% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 6 prior). Their most common stage is series-a (54% of deals). Average disclosed round size is $64.7M (across 18 rounds with reported amounts).

    Find people at LifeArc Ventures on Goldilocks AI

    Portfolio

    22

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    3

    Team

    CT

    Clare Terlouw

    Managing Partner

    OC

    Olivia Cavlan MD

    Partner

    SM

    Sohaib Mir

    Partner

    CB

    Chris Baker

    Investment Principal

    DR

    Diana Röttger

    Investment Principal

    JN

    Jonathan Nash

    Investment Principal

    EC

    Etienne Cousin

    Investment Associate

    ML

    Matthew Lulham-Robinson

    Investment Associate

    DH

    Deborah Harland

    Chair, LifeArc Ventures Investment Committee

    Dr Ian Gilham

    Dr Ian Gilham

    Chair of Board of Trustees

    Sam Barrell

    Sam Barrell

    Chief Executive Officer (CEO)

    Stéphane Maikovsky

    Stéphane Maikovsky

    Deputy Chief Executive Officer and Chief Financial Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    28 investments
    CompanyRoundAmountDate
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJun 2026
    Cytospire Therapeutics logoCytospire TherapeuticsSeries A—May 2026
    Exciva logoExcivaSeries B—Jan 2026
    Cytospire Therapeutics logoCytospire TherapeuticsSeries A$61MJan 2026
    RQ Biotechnology logoRQ BiotechnologySeries A$115MJan 2026
    GlycoEra logoGlycoEraSeries B$130MMay 2025
    Tribune Therapeutics logoTribune TherapeuticsSeries A—Apr 2025
    Hillstar Bio logoHillstar BioSeries A$67MMar 2025
    Exciva logoExcivaSeries B$59MJan 2025
    HHillstarSeries A$67MJan 2025
    Maxion logoMaxionSeries A$72MJan 2025
    MMaxion Therapeutics Ltd.Series A$72MJan 2025
    Hillstar Bio logoHillstar BioSeries A$67MJan 2025
    FLUID BIOMED logoFLUID BIOMEDSeries A$27MDec 2024
    Ozlo Sleep logoOzlo SleepUnknown$12MOct 2024
    MMaxion Therapeutics Ltd.Series A$16MFeb 2024
    FLUID BIOMED logoFLUID BIOMEDSeries A$27MJan 2024
    OOzloUnknown$12MJan 2024
    OOxford Cancer Analytics (OXcan)Seed—Jan 2023
    Climb Bio logoClimb BioSeries B$60MMay 2021
    EEliem TherapeuticsSeries B$60MMay 2021
    BBrainWaveBankSeed—Jul 2020
    Springworks logoSpringworksSeries B$125MJan 2019
    Ikarovec logoIkarovecSeed——
    Surgery Hero logoSurgery HeroSeed——
    Page 1 of 2

    Top Co-Investors

    Last updated: 7 October 2026